Table 2

 Trials of the use of GP IIb/IIIa inhibitors in coronary intervention

Trial (ref) Patient (n) Year of commencement Duration of drug infusion (h) Indication for intervention AMI (%) Unstable angina (%)
Abciximab
 EPIC (26)2099199112High risk1923
 EPILOG (30)2792199512Any intervention046
 CAPTURE (32)1265199318–24Unstable angina0100
 RAPPORT (42)483199512Primary angioplasty1000
 EPISTENT (39)2399199512Any angioplasty or stenting162-150 35
Eptifibatide
 IMPACT II (35)4010199320–24Any intervention438
Tirofiban
 RESTORE (33)2141199536Unstable angina or MI26 + 72-160 67
  • EPIC: Evaluation of Platelet IIb/IIIa inhibition to prevent Ischaemic Complications trial; EPILOG: Evaluation in PTCA to improve Long-term Outcome with Abciximab GP IIb/IIIa blockade; CAPTURE: c7E3 Fab AntiPlatelet Therapy in Refractory Unstable Angina; RAPPORT: ReoPro and Primary PTCA Organisation and Randomised Trial; EPISTENT: Evaluation of Platelet GP IIb/IIIa Inhibitor for Stenting trial; IMPACT II: Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis trial; RESTORE: Randomised Efficacy Study of Titofiban for Outcomes and Restenosis.

  • 2-150 MI within 7 days data for acute MI as the admitting event not given;

  • 2-160 26% following the acute phase of MI and 7% primary PTCA.